share_log

Travere Therapeutics Shares Are Trading Higher After Wedbush Maintained an Outperform Rating on the Stock and Raised Its Price Target From $17 to $25.

Benzinga ·  Oct 10 00:33
Travere Therapeutics Shares Are Trading Higher After Wedbush Maintained an Outperform Rating on the Stock and Raised Its Price Target From $17 to $25.
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
    Write a comment